Ketek News RSS Feed - Lawyer Seek Litigation http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/ What is Ketek? Ketek, which has the generic name of telithromycin, is marketed by Aventis Pharmaceuticals, Inc. Ketek is an antibiotic that is prescribed for the treatment of some respiratory infections, including lung and sinus infections. It received its FDA approval in 2004 for the treatment of community-acquired pneumonia, acute bacterial sinusitis, acute bacterial infections from chronic bronchitis. Ketek was the first ketolide approved by the FDA. ... en-us Accident Raises Safety Concerns About Chinese Tireshttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/Wall Street Journal reports that more than 450,000 Chinese-made tires may lack an important safety feature. Accident Raises Safety Concerns About Chinese Tireshttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/Wall Street Journal reports that more than 450,000 Chinese-made tires may lack an important safety feature FDA Curbs Use of Ketekhttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/Federal regulators Monday narrowed the approved uses of the controversial antibiotic Ketek, and said they will add new safety warnings for the drug. FDA limits use of risky Sanofi antibiotic Ketekhttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/ Sanofi-Aventis SA's antibiotic Ketek should no longer be used to treat sinusitis and bronchitis, U.S. officials warned on Monday, saying the controversial drug was too risky to treat those diseases. FDA tightens labeling, indications for Ketekhttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/The Food and Drug Administration on Monday announced labeling changes for the antibiotic Ketek, stripping it of two previously approved indications and adding a black-box warning, the agency's stronge... Sanofi's Ketek Is Restricted by U.S. Before Hearing (Update6)http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/Feb. 12 (Bloomberg) -- Sanofi-Aventis SA was banned from selling its Ketek antibiotic in the U.S. for bronchitis and sinusitis a day before lawmakers debate the safety of the drug. A dozen liver damage reports cited in Ketek patientshttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/ U.S. regulators have received 12 reports of acute liver failure in patients who took the Sanofi-Aventis antibiotic Ketek, a Food and Drug Administration official said on Thursday after the company an... Sanofi Aventis Puts New Warning on Ketekhttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/ French pharmaceutical company Sanofi-Aventis said Thursday it is updating prescribing information on its antibiotic Ketek to reflect new safety data. New Bold Warning Added to Ketekhttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/Sanofi-aventis said Thursday it has added a new bolded warning to the labeling of its antibiotic Ketek (telithromycin). FDA official urged halt to Ketek trial on kids: NYThttp://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/Ketek-P91/News/ A U.S. health official last month called for French drugmaker Sanofi-Aventis to halt clinical trials of its antibiotic Ketek in children because the drug could be deadly, a newspaper reported on Thur...